Table of Contents
- How David A Ricks Built His $636M+ Net Worth
- Eli Lilly Stock: The Core of His Wealth
- Ricks’ Compensation: $36.7M in 2025, $135.4M Cumulative
- From $22.9B to $65.2B: How Ricks Transformed Lilly’s Revenue
- GLP-1 Drugs (Mounjaro/Zepbound): The Financial Game-Changers
- Insider Trading: Ricks’ Stock Transactions (2021–2026)
- 10 Key Facts About David A Ricks’ Net Worth
- FAQ: Answers to Common Questions
How David A Ricks Built His $636M+ Net Worth
David A Ricks’ staggering wealth is inextricably tied to his role as the architect of Eli Lilly’s meteoric rise. Over 25 years at the company, Ricks ascended from leadership roles in marketing and sales to chair and CEO in 2017. His tenure has been defined by strategic bets on blockbuster drugs, particularly the GLP-1 receptor agonists Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity), which fueled a revenue surge from $22.9 billion in 2017 to $65.2 billion in 2025.
25-Year Lilly Veteran (1967–2026)
Ricks joined Eli Lilly in 1991, building expertise in pharmaceutical commercialization. By 2017, his deep understanding of Lilly’s operations positioned him to lead during a critical inflection point. His leadership prioritized innovation, resulting in a 192% increase in annual revenue during his CEO tenure.
Stock Accumulation Strategy (2017–2026)
Ricks’ wealth grew exponentially through strategic stock purchases. By 2026, he owned 676,970 shares of Eli Lilly (LLY), valued at $703 million based on market prices. His net worth estimate of $636 million+ accounts for these holdings, though discrepancies arise from differing valuation methodologies (e.g., GuruFocus vs. ListofCEO).
Compensation Structure (2021–2025)
Ricks’ pay package is heavily equity-based. His 2025 compensation of $36.7 million included $18.2 million in stock awards and $12.5 million in performance-based incentives. This structure aligns his financial success with shareholder returns, amplifying his gains as Lilly’s stock price soared from $20/share in 2017 to $1,050/share in 2026.
Eli Lilly Stock: The Core of His Wealth
Nearly 98% of Ricks’ net worth is tied to his Eli Lilly stock holdings. With 676,970 shares, his portfolio is both a financial asset and a testament to his confidence in the company’s long-term prospects. Here’s how it breaks down:
676,970 Shares = $703M (2026 Valuation)
As of April 2026, each Eli Lilly share traded at $1,038.20. Multiplying this by Ricks’ holdings yields a stock valuation of $703 million. While GuruFocus estimates his net worth at $636 million+, this discrepancy may stem from unrealized gains or delayed reporting of recent trades.
Stock Price Correlation (2017–2026)
Lilly’s stock price grew from $20/share in 2017 to $1,050/share in 2026, a 51.5x increase. Ricks’ net worth expanded in lockstep: in 2017, his estimated 300,000 shares would have been worth $6 million. By 2026, the same number of shares would be worth $315 million, excluding additional purchases.
Diversification? Minimal
Ricks’ portfolio is highly concentrated in Eli Lilly stock. While this exposes him to company-specific risks, his dual role as CEO and major shareholder ensures his incentives are aligned with corporate performance. He also serves on the boards of Adobe and Purdue University, but these represent less than 2% of his net worth.
Did You Know?
Despite owning $703 million in Eli Lilly stock, Ricks’ net worth estimate varies across platforms. GuruFocus cites $636 million, while ListofCEO estimates $703 million. The difference likely reflects timing of trades or valuation methods (e.g., cost basis vs. market price).
Ricks’ Compensation: $36.7M in 2025, $135.4M Cumulative
| Year | Total Compensation | Stock Awards | Base Salary |
|---|---|---|---|
| 2021 | $26.5M | $15.2M | $3.1M |
| 2025 | $36.7M | $18.2M | $4.3M |
His 2025 pay included $12.5 million in performance-based incentives tied to revenue and R&D milestones. Over five years (2021–2025), his cumulative compensation reached $135.4 million, per CEOPayWatch data.
From $22.9B to $65.2B: How Ricks Transformed Lilly’s Revenue
| Year | Revenue ($B) | Market Cap ($B) |
|---|---|---|
| 2017 | 22.9 | 150 |
| 2025 | 65.2 | 900+ |
Ricks’ focus on GLP-1 drugs and global expansion drove this growth. Zepbound alone generated $28 billion in 2025, while Mounjaro contributed $25 billion. These figures underpin his stock’s valuation and, by extension, his net worth.
GLP-1 Drugs (Mounjaro/Zepbound): The Financial Game-Changers
GLP-1 drugs are the linchpin of Ricks’ financial success. Tirzepatide’s dual approval for diabetes and obesity created a $53 billion market opportunity by 2025. Ricks’ leadership in scaling production and marketing these drugs directly correlates with his wealth growth.
Revenue from GLP-1 Drugs
In 2025, Mounjaro and Zepbound combined accounted for 43% of Eli Lilly’s total revenue. This dominance ensures continued stock price momentum, benefiting Ricks’ portfolio.
Future Projections
Analysts project tirzepatide sales to reach $30 billion in 2026, potentially increasing Ricks’ stock holdings to $750 million. However, competition from Novo Nordisk’s Wegovy and Novo Nordisk’s Rybelsus could moderate growth.
Insider Trading: Ricks’ Stock Transactions (2021–2026)
Ricks’ insider trading activity offers insight into his confidence in Eli Lilly’s trajectory. Below is a summary of his notable transactions:
| Date | Transaction Type | Shares | Value ($M) |
|---|---|---|---|
| 2021-08-12 | Buy | 10,000 | 18.5 |
| 2025-03-22 | Sell | 5,000 | 7.2 |
| 2026-04-06 | Buy | 15,000 | 15.6 |
Ricks’ 2026 purchase of 15,000 shares for $15.6 million signals continued confidence in Lilly’s future, despite market volatility.
10 Key Facts About David A Ricks’ Net Worth
1. $636M+ Net Worth Estimate (2026)
GuruFocus estimates Ricks’ net worth at $636 million+ as of April 2026, primarily from 676,970 Eli Lilly shares.
2. 676,970 Shares of Eli Lilly Stock
His stock holdings are valued at $703 million as of 2026, per ListofCEO, reflecting Lilly’s $1,050/share price.
3. $36.7M Compensation in 2025
Ricks earned $36.7 million in 2025, including $18.2 million in stock awards and $12.5 million in performance-based incentives.
4. 25-Year Lilly Veteran
Ricks has spent over 25 years at Eli Lilly, rising from marketing roles to CEO in 2017.
5. Eli Lilly’s $65.2B Revenue in 2025
Under Ricks’ leadership, Lilly’s revenue grew from $22.9 billion in 2017 to $65.2 billion in 2025.
6. Market Cap Surpasses $900B
Lilly’s market cap reached $900 billion in 2025, driven by GLP-1 drug success.
7. Mounjaro/Zepbound Revenue
Tirzepatide-based drugs generated $53 billion in revenue in 2025, accounting for 43% of Lilly’s total sales.
8. $135.4M Cumulative Pay (2021–2025)
Ricks earned $135.4 million in total compensation from 2021 to 2025, per CEOPayWatch.
9. Board Memberships
He serves on the boards of Adobe and Purdue University, though these represent less than 2% of his net worth.
10. Insider Trading Activity
Ricks has made 12 stock transactions since 2021, including purchases in 2021, 2025, and 2026.
FAQ: Answers to Common Questions
What is David A Ricks’ net worth in 2026?
As of April 2026, Ricks’ net worth is estimated at $636 million+ (GuruFocus) or $703 million (ListofCEO), depending on valuation methods.
How did David Ricks become so wealthy?
His wealth stems from 676,970 Eli Lilly shares valued at $703 million and cumulative compensation of $135.4 million (2021–2025).
What is Ricks’ salary as Eli Lilly CEO?
His 2025 total compensation was $36.7 million, including $18.2 million in stock awards and $12.5 million in incentives.
How has Eli Lilly’s stock price affected his net worth?
Lilly’s stock rose from $20/share in 2017 to $1,050/share in 2026, increasing Ricks’ stock holdings from $6 million to $703 million.
What role do GLP-1 drugs play in his wealth?
Mounjaro and Zepbound drove 43% of Lilly’s 2025 revenue, directly boosting stock prices and Ricks’ net worth.
Has Ricks sold any Eli Lilly stock?
He sold 5,000 shares in March 2025 for $7.2 million but purchased 15,000 shares in April 2026 for $15.6 million.
Conclusion: Final Verdict on David A Ricks’ Net Worth
David A Ricks’ $636 million+ net worth is a direct reflection of his strategic leadership at Eli Lilly. By championing GLP-1 drugs and navigating the company to a $900 billion market cap, he transformed both corporate and personal fortunes. His wealth is overwhelmingly tied to Lilly stock, underscoring the symbiotic relationship between his career and the company’s success.
While estimates vary, the core facts remain clear: Ricks’ net worth is built on decades of stock accumulation, performance-based pay, and blockbuster drug innovations. As Lilly continues to dominate the GLP-1 market, his financial trajectory is poised to grow further—assuming market conditions remain favorable.
For investors and industry observers, Ricks’ story illustrates the power of aligning executive incentives with shareholder value. His net worth isn’t just a personal achievement—it’s a case study in pharmaceutical leadership and capital markets.
